Compare MSBI & SGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MSBI | SGP |
|---|---|---|
| Founded | 1881 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 668.5M | 650.9M |
| IPO Year | 2011 | 2026 |
| Metric | MSBI | SGP |
|---|---|---|
| Price | $33.54 | $24.88 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $24.33 | ★ $45.00 |
| AVG Volume (30 Days) | ★ 175.4K | 87.7K |
| Earning Date | 04-23-2026 | 05-15-2026 |
| Dividend Yield | ★ 5.00% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.56 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $18.41 | N/A |
| Revenue Next Year | $2.07 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.24 | $17.06 |
| 52 Week High | $35.10 | $30.56 |
| Indicator | MSBI | SGP |
|---|---|---|
| Relative Strength Index (RSI) | 59.89 | 67.27 |
| Support Level | $29.78 | $20.95 |
| Resistance Level | N/A | $25.83 |
| Average True Range (ATR) | 0.93 | 1.35 |
| MACD | -0.07 | 0.35 |
| Stochastic Oscillator | 68.35 | 82.64 |
Midland States Bancorp Inc is a diversified financial holding company. The company provides a full range of commercial and consumer banking products and services, business equipment financing, merchant credit card services, trust and investment management, and insurance and financial planning services. The Banking segment, which generates the majority of the revenue, provides financial products and services to consumers and businesses, including commercial, commercial real estate, mortgage, and other consumer loan products; commercial equipment financing, etc. The Wealth Management segment consists of trust and fiduciary services, brokerage, and retirement planning services. The Corporate segment includes the holding company's financing and investment activities, administrative expenses.
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.